CV

CV is in a Stage 2 advancing phase with a bullish medium-term bias reinforced by higher highs and higher lows, rising short-term EMAs, and low transition risk. Price is currently extended above key EMAs without a clear pullback, so execution should be deferred into structural support zones rather than pursued on the current extension.

• ↑167k patients scanned with Capsule Chem Plus, showing robust adoption.
• ↑AI integration expected to cut wait times and boost workflow efficiency.
• ↓Net loss of $7.9M in Q3 2025; operating loss widened to $8.4M in Q1 2026.